SCHOTT Pharma AG & Co. KGaA

Total Valuation

SCHOTT Pharma AG & Co. KGaA carries a market capitalization of 2.71B, placing it among publicly traded companies globally. Its enterprise value stands at 2.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

SCHOTT Pharma AG & Co. KGaA currently has 150.61M shares outstanding.

Valuation Ratios

SCHOTT Pharma AG & Co. KGaA trades at a trailing price-to-earnings ratio of 14.16. The price-to-sales ratio is 2.05, and the price-to-book ratio stands at 13.48.

Enterprise Valuation

On an enterprise value basis, SCHOTT Pharma AG & Co. KGaA trades at an EV/EBITDA multiple of 11.10 and an EV/FCF ratio of 5.54. The EV/Sales ratio of 2.02 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 11.10 provides insight into valuation relative to core operating earnings.

Financial Position

SCHOTT Pharma AG & Co. KGaA maintains a current ratio of 1.59, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

SCHOTT Pharma AG & Co. KGaA posts a return on equity of 95.15 and a return on invested capital of 14.69.

Taxes

Over the trailing twelve months, SCHOTT Pharma AG & Co. KGaA has paid 40.44M in income taxes, reflecting an effective tax rate of 21.95.

Stock Price Statistics

SCHOTT Pharma AG & Co. KGaA's stock has declined approximately -29.27308% over the past 52 weeks. The 50-day moving average sits at 16.62, while the 200-day moving average is 16.27.

Income Statement

Over the trailing twelve months, SCHOTT Pharma AG & Co. KGaA generated 992.11M in revenue and converted that into 143.31M in net income, yielding earnings per share of 0.96. EBITDA reached 180.09M, while operating income came in at 180.09M.

Balance Sheet

Total book value stands at 150.62M, with working capital of 247.51M providing operational flexibility.

Cash Flow

SCHOTT Pharma AG & Co. KGaA produced 202.46M in operating cash flow over the past twelve months. After subtracting -143.85M in capital expenditures, free cash flow totaled 58.61M - equivalent to 0.39 per share.

Margins

SCHOTT Pharma AG & Co. KGaA operates with a gross margin of 32.96, reflecting its pricing power and cost economics. The operating margin of 18.15 and net profit margin of 14.45 provide insight into operational efficiency.

Dividends & Yields

Scores

SCHOTT Pharma AG & Co. KGaA posts an Altman Z-Score of 3.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.